In this report, we examined plasma stromal cell-derived factor-1 levels in normal healthy donors for allogeneic peripheral blood stem cell transplantation (PBSCT) and in patients for autologous PBSCT using an enzyme-linked immunosorbent assay. The average level of plasma stromal cell-derived factor-1 was 2197 pg/ml before granulocyte colony-stimulating factor administration and 1899 pg/ml on day 4, demonstrating a significant decrease in the peripheral blood of healthy donors (P ¼ 0.0003). In patients for autologous PBSCT, a significant decrease of plasma stromal cell-derived factor-1 in the peripheral blood was also observed (P ¼ 0.0464). However, the physiologic gradient of stromal cell-derived factor-1 between peripheral blood and bone marrow was never inverted in normal healthy donors or in autologous PBSCT patients. Our results suggest that stromal cellderived factor-1 may not be involved in the granulocyte colony-stimulating factor-induced release of CD34 + cells to the peripheral blood. Further studies of a possible additive effect of granulocyte colony-stimulating factor and stromal cell-derived factor-1 are warranted.
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3-6 Recently, Wright et al 11 reported that HPC migrated only in response to SDF-1a. In this report, we measured plasma SDF-1 levels in PBSC mobilization induced by G-CSF alone and by G-CSF plus chemotherapy to evaluate any biological role of SDF-1 in the mechanism of stem cell migration.
Materials and methods

Patient population
Between November 1999 and June 2002, 20 healthy donors and six patients, who had been referred to the Okayama University Hospital (Okayama, Japan) for clinical indications of PBSC leukapheresis for allogeneic and autologous PBSCT, were entered into this study after informed consent was obtained. The median age of the healthy donors and patients for autologous PBSCT was 46.5 and 53 years old, respectively (range: 16-63 and 29-68 years, respectively). There were seven males and 13 females. In patients for autologous PBSCT, there were three males and three females. Diagnoses of patients for autologous PBSCT were non-Hodgkin's lymphoma (NHL) in two, small cell lung cancer (SCLC) in two, multiple myeloma (MM) in one, and breast cancer in one.
Mobilization regimens and collection of PBSC
All healthy donors received G-CSF (Filgrastim: KirinSankyo Co Ltd, Tokyo, Japan) administration at a dose of 400 mg/m procedures were initiated from day 4. In patients for autologous PBSCT, the choice of a mobilization procedure was dictated by diagnosis, disease status and clinical protocols in which patients were enrolled. Two patients were treated with the PE regimen (cisplatin: 80 mg/m 2 once daily i.v. on day 1; etoposide: 240 mg/m 2 once daily i.v. on days 1-3), one with high-dose etoposide (500 mg/m 2 for 3 days), one with high-dose cyclophosphamide (2,000 mg/m 2 for 2 days). G-CSF (Filgrastim: Kirin-Sankyo Co. Ltd, Tokyo, Japan in two, Lenograstim: Chugai Co Ltd, Tokyo, Japan in four) was started on the day of the nadir of neutrophils at a dose of 5 mg/kg intravenously or 2 mg/kg subcutaneously.
The method of PBSC collection has been reported previously. 12, 13 Leukapheresis was performed with a continuous-flow blood cell separator (Spectra, COBE BCT, Lakewood, CO, USA). The blood volumes processed were 200 and 150 ml/kg of patient's body weight for allogeneic and autologous PBSCT, respectively. Daily leukapheresis was repeated usually two or three times to achieve the target of 2-5 Â 10 6 CD34 + cells/kg.
Enumeration of CD34 + cells
The number of CD34 + cells collected was determined by a modified flow cytometric analysis technique. 13, 14 The median numbers of MNC collected from healthy donors for allogeneic PBSCT and patients for autologous PBSCT were 699. 
Determination of SDF-1
Before and after administration of G-CSF, plasma samples for SDF-1 were collected from PB and BM, and were stored at À201C. Plasma SDF-1 levels were analyzed by a sandwich enzyme-linked immunosorbent assay (ELISA) using anti-SDF-1a antibody (R&D Systems, Minneapolis, MN, USA). Patient's samples were run in duplicates.
Statistical analysis
Associations among various factors related to PBSC collection were analyzed using the Wilcoxon signed-rank test. A level of Po0.05 was considered to be statistically significant.
Results
Time courses of plasma SDF-1 levels in five healthy donors are shown in Table 1 . The average level of plasma SDF-1 was 2217 pg/ml on day 1 before G-CSF administration, 2234 pg/ml on day 2, 2145 pg/ml on day 3, 2126 pg/ml on day 4, and 2003 pg/ml on day 5. A transient increase of plasma SDF-1 levels was observed on day 2, and a decrease of plasma SDF-1 levels was observed as early as day 3 and continued until day 5. In 20 healthy donors, on day 1 before G-CSF administration, the average level of SDF-1 was 2249 pg/ml and had significantly decreased to 1973 pg/ ml on day 4 ( Figure 1 , P ¼ 0.0003). SDF-1 levels in PB and BM at days 1 and 4 of two healthy donors are shown in Figure 2 . The level of plasma SDF-1 in PB was 2002 pg/ml (a) and 2343 pg/ml (b) on day 1, 1777 pg/ml (a) and 2292 pg/ml (b) on day 4, respectively. The level of plasma SDF-1 in BM was 5916 pg/ml (a) and 3022 pg/ml (b) on day 1, 3870 pg/ml (a) and 3594 pg/ml (b) on day 4, respectively. Although a decrease of plasma SDF-1 level in PB was observed in both donors, SDF-1 levels in the BM were consistently higher than in PB at days 1 and 4.
The average of SDF-1 levels in PB and BM before and after G-CSF administration to the six patients for autologous PBSCT are shown in Figure 3 . Consistent with the results in healthy donors, a significant decrease of plasma SDF-1 levels in PB was observed (before G-CSF: 1655 vs after G-CSF: 1234 pg/ml: P ¼ 0.0464). The average of SDF-1 levels in BM was 3108 pg/ml before G-CSF administration and 2927 pg/ml after G-CSF administration. SDF-1 levels in BM were always higher than in PB before and after G-CSF administration, and the physiologic gradient of SDF-1 between PB and BM was never inverted.
Discussion
To evaluate any biological role of SDF-1 in the mechanism of stem cell migration, we measured plasma levels in G- CSF-induced PBSC mobilization. Gazitt and Liu 10 reported that SDF-1 levels in the apheresis product of the 'good mobilizers' were significantly lower than the apheresis product of the 'poor mobilizers' in autotransplant patients with NHL (288782 vs 5837217 pg/ml; P ¼ 0.0009). Because no 'poor mobilizers' were observed in our small number of autologous PBSCT patient/ subjects, we could not perform similar statistical analysis and draw any conclusion. In the settings of 'good' and 'poor' mobilizers as CD34 + 420 Â 10 6 and o20 Â 10 6 /l processed blood volume, 1 respectively, plasma SDF-1 levels in PB were not significantly associated with the outcome of mobilization in normal healthy donors (data not shown). On the other hand, two reports of engineered increases of SDF-1 level in PB have been associated with mobilization. 8, 15 Increases in circulating progenitors were noted 24-48 h after injection of a high amount of an N-terminalmodified analog of SDF-1, MetSDF-1b, which had enhanced functional activity. 8 Hattori et al 15 also reported that plasma elevation of SDF-1 induces mobilization of HPCs in in vivo studies.
In the present study, a significant decrease of plasma SDF-1 levels in PB during G-CSF administration was observed. However, SDF-1 levels in BM were always higher than in PB, and the gradient of SDF-1 levels between PB and BM maintained the same pattern (PB o BM). We evaluated the correlation between the degree of plasma SDF-1 depression (before-after G-CSF administration) in PB and the number of CD34 + cells collected in healthy donors and patients for autologous PBSCT. Among these parameters, however, correlations were not observed (data not shown). Sweeney et al 16 reported that plasma SDF-1 in PB increased rapidly and dramatically after treatment with sulfated polysaccharide fucoidan in monkeys and mice, coinciding with decreased levels in BM. They reported that both a decrease of bound SDF-1 within BM and a disruption of the physiologic chemokine gradient after release of soluble SDF-1 into the periphery (from BM or other tissues) could trigger mobilization of HPCs to the periphery. 16 If these facts are considered, our results suggest that SDF-1 may not be involved in the G-CSF-induced release of CD34 + cells to PB. As alternative regimens for PBSC mobilization, combinations of G-CSF and SDF-1, MetSDF-1b or fucoidan may have higher efficacy than G-CSF alone.
In conclusion, this is a first report to confirm a significant decrease in plasma SDF-1 levels during G-CSF-induced PBSC mobilization of normal healthy donors. However, the significance of these kinetics remains unclear. Further studies will be necessary to determine the exact role of SDF-1 in the process of mobilization. PBSCT. Plasma SDF-1 average levels in PB and BM before and after G-CSF administration are shown. Results were derived from six patients for autologous PBSCT; bars represent mean7s.d.
